Reduces Asthma Symptoms

PULMICORT RESPULES significantly reduces nighttime and daytime asthma symptoms^2,3

Caregivers reported asthma symptoms as mild at baseline.

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.²³

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.²³

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.²³

Among more than 340 children aged 12 months to 8 years, Kemp and colleagues showed that once-daily PULMICORT RESPULES significantly²

• Decreased nighttime asthma symptom scores
• Decreased daytime asthma symptom scores
• Reduced the use of short-acting rescue ß₂-agonists

Study design^2,3

• Multicenter, double-blind, placebo-controlled, parallel-group study to determine efficacy and safety of once-daily doses of PULMICORT RESPULES
• 343 pediatric patients (12 months to 8 years of age) with mild, persistent asthma randomized to receive 0.25 mg, 0.5 mg, 1 mg, or placebo for 12 weeks
• Nighttime and daytime asthma symptoms were rated on a 4-point scale: 0=none; 1=mild (awareness of asthma symptoms that were easily tolerated); 2=moderate (asthma symptoms with some discomfort, causing some interference to sleep or daily activities); 3=severe (incapacitating asthma symptoms, with inability to sleep or perform daily activities)